Print

Featured Studies Results

Study Type: Treatment

Evaluating the Benefit of Adding ART6043 to Olaparib for HER2-Negative Metastatic or Advanced Breast Cancer and a BRCA Mutation (POLKA)

https://www.facingourrisk.org/research-clinical-trials/study/430 /evaluate-the-benefit-of-adding-art6043-to-olaparib-for-her2-negative-metastatic-or-advanced-breast-cancer-and-a-gbrca-mutation-polka

Clinicaltrials.gov identifier:
NCT05898399 (https://clinicaltrials.gov/show/NCT05898399)

Treatment
Metastatic breast cancer treatment study


A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone or Darolutamide (TALENT)

https://www.facingourrisk.org/research-clinical-trials/study/425 /a-study-of-talazoparib-with-or-without-enzalutamide-in-people-with-prostate-cancer-who-have-previously-received-abiraterone-or-darolutamide-talent

Clinicaltrials.gov identifier:
NCT06844383 (https://clinicaltrials.gov/show/NCT06844383)

Treatment
Study for metastatic castration-resistant prostate cancer with an HRR mutation


ERADICATE: Hormone and Targeted Therapy for HR+/HER2-Low Advanced Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/447 /eradicate-hormone-and-targeted-therapy-for-hrher2-low-advanced-breast-cancer

Clinicaltrials.gov identifier:
NCT07198724 (https://clinicaltrials.gov/show/NCT07198724)

Treatment
Study of hormone and targeted therapy for advanced breast cancer


Using a Computer Model to Identify Treatment Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

https://www.facingourrisk.org/research-clinical-trials/study/438 /using-a-computer-model-to-identify-treatment-options-in-advanced-metastatic-breast-cancer-synthesis-breast

Clinicaltrials.gov identifier:
NCT07067138 (https://clinicaltrials.gov/show/NCT07067138)

Treatment
Treatment study for people with metastatic breast cancer


Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

https://www.facingourrisk.org/research-clinical-trials/study/356 /treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies

Clinicaltrials.gov identifier:
NCT06974110 (https://clinicaltrials.gov/show/NCT06974110)

Treatment
Treatment study for people with advanced or metastatic cancers


A New Drug, DT2216, Combined With Paclitaxel for Recurrent Platinum-Resistant Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/429 /a-new-drug-dt2216-combined-with-paclitaxel-for-recurrent-platinum-resistant-ovarian-cancer

Clinicaltrials.gov identifier:
NCT06964009 (https://clinicaltrials.gov/show/NCT06964009)

Treatment
Treatment study for people with recurrent platinum-resistant ovarian cancer


Comparing Treatment with Sacituzumab Govitecan and Bevacizumab to Chemotherapy and Bevacizumab for Recurrent Ovarian Cancer After PARP Inhibitor Maintenance Therapy

https://www.facingourrisk.org/research-clinical-trials/study/439 /comparing-investigational-drug-combination-sacituzumab-govitecan-with-bevacizumab-to-chemotherapy-for-treating-recurrent-ovarian-cancer-after-parp-inhibitor-maintenance-therapy

Clinicaltrials.gov identifier:
NCT07504588 (https://clinicaltrials.gov/show/NCT07504588)

Treatment
Study for platinum-sensitive ovarian cancer that has progressed after PARP inhibitor


Study of Dostarlimab Immunotherapy in People with Mismatch Repair-Deficient Endometrial Cancer Who Wish to Preserve Fertility

https://www.facingourrisk.org/research-clinical-trials/study/434 /a-phase-ii-study-of-dostarlimab-immunotherapy-in-people-with-mismatch-repair-deficient-endometrial-who-wish-to-preserve-fertility

Clinicaltrials.gov identifier:
NCT04165772 (https://clinicaltrials.gov/show/NCT04165772)

Treatment
Treatment study for people with MSI-H or dMMR early-stage endometrial cancer


A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer who Progressed After a Prior Line of Treatment

https://www.facingourrisk.org/research-clinical-trials/study/414 /a-study-to-learn-about-the-study-medicine-called-pf-07248144-in-combination-with-fulvestrant-in-people-with-hr-positive-her2-negative-advanced-or-metastatic-breast-cancer-who-progressed-after-a-prior-line-of-treatment

Clinicaltrials.gov identifier:
NCT07062965 (https://clinicaltrials.gov/show/NCT07062965)

Treatment
Study for adults with advanced/metastatic HR-positive, HER2-negative breast cancer who have progressed from prior treatment


Comparing Shorter vs. Standard Radiation for High-Risk Prostate Cancer (High Five)

https://www.facingourrisk.org/research-clinical-trials/study/397 /comparing-shorter-vs-standard-radiation-for-high-risk-prostate-cancer

Clinicaltrials.gov identifier:
NCT05946213 (https://clinicaltrials.gov/show/NCT05946213)

Treatment
Treatment study for high-risk prostate cancer


Testing the Drug CX-5461 for Treating Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/431 /testing-the-drug-cx-5461-for-treating-metastatic-solid-tumors

Clinicaltrials.gov identifier:
NCT06606990 (https://clinicaltrials.gov/show/NCT06606990)

Treatment
Phase 1 study for treatment of advanced solid tumors


Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)

https://www.facingourrisk.org/research-clinical-trials/study/389 /using-the-drug-daraxonrasib-in-surgically-removed-pancreatic-cancer-rasolute-304

Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)

Treatment
Study for pancreatic cancer treatment after surgery and chemotherapy


Comparing the Targeted Therapy Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (RASolute 303)

https://www.facingourrisk.org/research-clinical-trials/study/407 /comparing-daraxonrasib-with-or-without-chemotherapy-to-chemotherapy-alone-for-first-line-treatment-of-metastatic-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT07491445 (https://clinicaltrials.gov/show/NCT07491445)

Treatment
Study for First-Line Treatment of Metastatic Pancreatic Cancer


Testing a New Targeted Therapy ETX-19477 to Treat Advanced Breast, Colorectal Endometrial, Ovarian or Pancreatic Cancer in People with a BRCA2 Mutation (ERADIC8)

https://www.facingourrisk.org/research-clinical-trials/study/432 /testing-a-new-targeted-therapy-etx-19477-to-treat-advanced-solid-tumors-eradic8

Clinicaltrials.gov identifier:
NCT06395519 (https://clinicaltrials.gov/show/NCT06395519)

Treatment
Treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer


Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning

https://www.facingourrisk.org/research-clinical-trials/study/378 /study-of-a-new-oral-medication-daraxonrasib-after-surgery-to-help-prevent-pancreatic-cancer-from-returning

Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)

Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery


Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery

https://www.facingourrisk.org/research-clinical-trials/study/386 /comparing-two-vaccine-treatments-with-immunotherapy-for-pancreatic-cancer-before-and-after-surgery

Clinicaltrials.gov identifier:
NCT06782932 (https://clinicaltrials.gov/show/NCT06782932)

Treatment
Treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment


Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)

https://www.facingourrisk.org/research-clinical-trials/study/371 /comparing-an-investigational-targeted-drug-azd5335-to-standard-treatments-in-people-with-platinumresistant-ovarian-cancer-trevioc01

Clinicaltrials.gov identifier:
NCT07218809 (https://clinicaltrials.gov/show/NCT07218809)

Treatment
Treatment study for platinum-resistant ovarian cancer


Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)

https://www.facingourrisk.org/research-clinical-trials/study/372 /using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle

Clinicaltrials.gov identifier:
NCT05059444 (https://clinicaltrials.gov/show/NCT05059444)

Treatment
Post-treatment study to monitor for recurrence


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.